Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
Contrary to the goal of onshoring critical industries, the U.S. is increasingly relying on Chinese biotech for new medicines. Drug in-licensing from China is projected to skyrocket from $5 billion in 2020 to an expected $60-70 billion by 2025, signaling a major shift in global pharmaceutical power.
Related Insights
Western pharma firms strategically license assets from Chinese biotechs while leaving China rights with the local partner. This leverages China's faster, cheaper clinical development, as the partner tests the molecule in new indications, generating valuable data that de-risks the asset for the global firm at no extra cost.
A notable trend is the licensing of advanced clinical assets from Chinese biotechs to major global pharmaceutical companies for ex-China rights. Deals like Roche licensing Medilink's Phase 3 ADC and AbbVie licensing Reamgen's Phase 2 bispecific antibody signal China's evolution from a market to a source of high-value, late-stage innovation.
China's growing dominance in pharmaceuticals is not accidental but a deliberate, 30-year national strategy. It began with cornering the market for low-cost active pharmaceutical ingredients (APIs), then generics, and now is focused on becoming the global leader in innovative biotech by 2035.
Western pharmaceutical companies are no longer seeking cheap 'me-too' assets in China. Instead, they are paying premium prices for genuinely innovative drugs, as evidenced by a 10x increase in deal size over five years and a surge in patent filings from the region.
Jeremy Levin outlines China's deliberate, 25-year strategic plan for biotech, moving from API production to CROs, attracting scientific talent, creating lookalikes, and now developing novel medicines. He warns that unless the U.S. treats biotech as a strategic asset, China's state-driven approach will make it the dominant innovator within five years, partly funded by Western pharma investments.
When a major US company like Bristol Myers Squibb invests in a Chinese biotech, it's not just a sign of global competition. It signifies a deliberate withdrawal of capital from the American biotech ecosystem. This migration of innovation and funding is a clear warning that the US is losing its strategic advantage.
Driven by significant government investment, China is rapidly becoming a leader in biotech R&D, licensing, and outsourcing. This shift is a top-of-mind concern for US biotech and pharma executives, with China now involved in a majority of top R&D licensing deals.
According to investor Joe Edelman, China's main strength is developing new molecules. This means US and European firms will increasingly in-license drugs from China, creating fierce competition for the small US biotechs that traditionally filled this pipeline role for larger pharmaceutical companies.
The increasing innovation and speed from China puts pressure on the U.S. biotech ecosystem. To remain competitive, the U.S. must focus on collaboration and address its own systemic issues, such as slow trial execution and the high cost of getting a drug to the IND stage.
The next decade in biotech will prioritize speed and cost, areas where Chinese companies excel. They rapidly and cheaply advance molecules to early clinical trials, attracting major pharma companies to acquire assets that they historically would have sourced from US biotechs. This is reshaping the global competitive landscape.
